ProLynx kündigt klinische Studie der Phase IB zu seinem DNA-schädigenden Wirkstoff PLX038 (PEG~SN-38) in Kombination mit dem PARP-Inhibitor Rubraca® (Rucaparib) am National Cancer Institute an

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs